Fig. 4: The Fc(A680)-VH4127 specifically targets subcutaneous pancreatic tumors. | Communications Biology

Fig. 4: The Fc(A680)-VH4127 specifically targets subcutaneous pancreatic tumors.

From: LDL receptor-peptide conjugate as in vivo tool for specific targeting of pancreatic ductal adenocarcinoma

Fig. 4

a Representative merged fluorescence and visible light images of Ldlr WT and Ldlr KO pancreatic tumors grown subcutaneously in immunodeficient mice. Fluorescence acquisitions were performed before intravenous injection (IV) of Fc(A680)-VH4127 conjugate (1 nmole/mouse) and 1, 4, and 24 h after. The kinetic of tumor-specific fluorescence of Fc(A680)-VH4127 (i.e., region of interest (ROI)) is illustrated and expressed as mean (ph/s/cm2/sr) ± s.e.m. b Representative merged fluorescence and visible light images of the tumors (Ldlr WT and Ldlr KO), pancreas (P), liver (L), adrenal glands (Ag) and kidney (K) acquired 24 h after administration of Fc(A680)-VH4127 conjugate. The tissue-specific fluorescence of Fc(A680)-VH4127 was illustrated and expressed as mean (ph/s/cm2/sr) ± s.e.m. a, b One-way ANOVA with post-hoc Tukey HSD test, ns: no significant difference, *p < 0.05, **p < 0.01, ***p < 0.001. n = 8–13 mice at each time-point.

Back to article page